Ładuje się......
The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?
A challenge for the clinician treating patients with multiple sclerosis (MS) is to determine the most effective treatment while weighing the benefits and risks. Results of the phase 2 and phase 3 studies on natalizumab were received with great interest, in part due to the “improved” risk reduction f...
Zapisane w:
| Główni autorzy: | , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
American Academy of Neurology
2009
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2754334/ https://ncbi.nlm.nih.gov/pubmed/19770475 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e3181b9c8f7 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|